A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2V617F myeloproliferative neoplasm

Leukemia Research

Volumn 34, Issue 4, 2010, Pages

  Veronese L ^a   Tchirkov, A ^a   Richard Pebrel, C ^b   Ledoux Pilon, A ^b   Fleury, J ^c   Chaleteix, C ^b   Goumy, C ^a   Gouas, L ^a   Berger, M G ^b   Vago, P ^a   Bay, J O ^b   Tournilhac, O ^b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b HÔTEL DIEU   (France)

^c Hôtel Dieu ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; JANUS KINASE 2; MESSENGER RNA; PHENYLALANINE; SALICYLIC ACID; VALINE;

ADULT; AGED; ASTHENIA; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; INFLAMMATORY DISEASE; IRON DEFICIENCY; KARYOTYPING; LETTER; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTOSIS; LOW DRUG DOSE; MALE; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOSIS; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHENYLALANINE; PIPERAZINES; PYRIMIDINES; THROMBOCYTOSIS; VALINE;

EID: 77049084048     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.025     Document Type: Letter

References (17)

1. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 434 (2005) 1144-1148
2. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365 (2005) 1054-1061
3. Kralovics R., Passamonti F., Buser A.S., Teo S.S., Tiedt R., and Passweg J.R. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352 (2005) 1779-1790
4. Jelinek J., Oki Y., Gharibyan V., Bueso-Ramos C., Prchal J.T., Verstovsek S., et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106 (2005) 3370-3373
5. Krämer A. JAK2-V617F and BCR-ABL-double Jeopardy?. Leukemia Res 32 (2008) 1489-1490
6. Bornhäuser M., Mohr B., Oelschlaegel U., Bornhäuser P., Jacki S., Ehninger G., et al. Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia Res 6 (2008) 993-995
7. Bocchia M., Vannucchi A.M., Gozzetti A., Guglielmelli P., Poli G., Crupi R., et al. Insights into JAK2-V617F mutation in CML. Lancet Oncol 8 (2007) 864-866
8. V617F-positive chronic idiopathic myelofibrosis. Leukemia Res 32 (2008) 1608-1610
9. Mirza I., Frantz C., Clarke G., Voth A.J., and Turner R. Transformation of polycythemia vera to chronic myelogenous leukemia. Arch Pathol Lab Med 131 (2007) 1719-1724
10. Gattenlohner S., Völker H.U., Etschmann B., Einsele H., and Müller-Hermelink H.K. BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T). Am J Hematol (2008) [Epub ahead of print]
11. Conchon M.R., Costa J.L., Novaes M.M., Dorlhiac-Llacer P.E., de Alencar Fischer Chamone D., and Bendit I. Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia. Int J Hematol 88 (2008) 243-245
12. V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 22 (2008) 1454-1455
13. V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21 (2007) 1103-1104
14. V617F mutation. Blood 109 (2007) 4106-4107
15. Krämer A., Reiter A., Kruth J., Erben P., Hochhaus A., Müller M., et al. JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukemia. Lancet Oncol 8 (2007) 658-660
16. V617F mutation is frequently present at diagnosis in patients with essential thrombocytemia and polycythemia vera. Blood 108 (2006) 1865-1867
17. Kralovics R., Teo S.S., Li S., Theocharides A., Buser A.S., Tichelli A., et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108 (2006) 1377-1380